US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by GreenLight Biosciences
GreenLight Announces Completion of Merger with Fall Line Endurance Fund
July 24, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private Transaction
May 30, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 11, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares
July 20, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Releases Inaugural Sustainability Report
April 12, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall Line
March 30, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results
March 28, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D Day
March 09, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D Day
March 07, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development Strategy
March 01, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate
February 01, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines
January 09, 2023
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 09, 2022
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences to Participate in Upcoming Investor Conferences in November
November 07, 2022
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences announces realignment to focus on near-term value drivers
October 12, 2022
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA
October 05, 2022
From
GreenLight Biosciences
Via
GlobeNewswire
Tickers
GRNA
